Mylan enters agreement with Gilead to develop new HIV drug

Mylan Laboratories Limited reached an agreement with Gilead Sciences Inc. on Monday to manufacture and distribute Tenofovir Alafenamide, an experimental HIV medication.

The non-exclusive agreement includes a clause that stipulates that Mylan can use the drug as both a single-agent product and in combination with other drugs.

"Mylan's mission is to provide the world's 7 billion people access to high-quality medicines and set new standards in health care,” Mylan CEO Heather Bresch said. “By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide in the countries hardest hit by this disease, we can help stem the tide of HIV/AIDS around the world."

As part of the agreement, Mylan will also receive a technology transfer from Gilead, which adds to Mylan’s agenda of helping the company manufacture low-cost versions of TAF for developing markets.

Phase III trials being conducted by Gilead Sciences met their primary objective, which was to prove TAF was a viable option for those infected by HIV.

The license granted to Mylan, which extends to 112 countries that together account for more than 30 million people living with HIV, represents 84 percent of the worldwide population infected with HIV.

Organizations in this Story


Want to get notified whenever we write about PharmiWeb ?
Next time we write about PharmiWeb, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.